SEC Form EFFECT filed by Aptevo Therapeutics Inc.
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | June 28, 2024 9:00 A.M. |
Form: | S-1 | ||||||
|
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | June 28, 2024 9:00 A.M. |
Form: | S-1 | ||||||
|
SEATTLE, WA / ACCESSWIRE / September 16, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that it has entered into securities purchase agreements with certain healthcare-focused and institutional investors to purchase (i) 9,090,910 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 18,181,820 shares of its common stock (the "Common Warrants") at a purchase price of $0.33 per share and associated Common Warrant in a registered direct offering pr
Early Data Indicate Clinical Activity in Patients with Multiple Solid Tumor TypesProlonged stable disease lasting >11 months demonstrated in Breast Cancer PatientFavorable Pharmacokinetics, Safety and Tolerability ObservedData Presented at the European Society of Medical Oncology on September 14, 2024 SEATTLE WA and LUND, SWEDEN / ACCESSWIRE / September 16, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) and Alligator Bioscience AB ("Alligator") (ATORX) today announced positive interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 for the treatment of solid tumors likely to express the tumor antigen 5T4. The results, which include clinical activity, sa
SEATTLE WA and LUND, SWEDEN / ACCESSWIRE / September 13, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) and Alligator Bioscience AB ("Alligator") (ATORX) today announced that positive interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 will be presented in a poster session on Saturday, September 14, 2024, at the European Society for Medical Oncology (ESMO) Annual Congress 2024, taking place September 13 th - 17 th , 2024 in Barcelona, Spain.Presentation DetailsPoster number: #668PTitle: First-in-Human Phase I Dose Escalation Study of ALG.APV-527, a 5T4 Tumor Antigen-Conditional 4-1BB Bispecific Antibody, in Patients with Advanced Solid Tumors, Demon
SC 13G - Aptevo Therapeutics Inc. (0001671584) (Subject)
SC 13G/A - Aptevo Therapeutics Inc. (0001671584) (Subject)
SC 13G/A - Aptevo Therapeutics Inc. (0001671584) (Subject)
Roth Capital reiterated coverage of Aptevo Therapeutics with a rating of Buy and set a new price target of $50.00 from $64.00 previously
424B4 - Aptevo Therapeutics Inc. (0001671584) (Filer)
EFFECT - Aptevo Therapeutics Inc. (0001671584) (Filer)
8-K - Aptevo Therapeutics Inc. (0001671584) (Filer)
4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independ
Shares of Domino’s Pizza, Inc. (NYSE:DPZ) fell sharply during Thursday's session after the company reported mixed quarterly results. The company reported second-quarter FY24 sales growth of 7.1% year-on-year to $1.097 billion, missing the analyst consensus estimate of $1.103 billion. The company is temporarily suspending its guidance metric of 1,100+ global net stores growth until the full effect of DPE's store opens and closures on international net store growth are known. Domino’s Pizza shares dipped 11.2% to $420.36 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Onconetix, Inc. (NASDAQ:ONCO) climbed 97.6% to $0.2944. On July 15, Oncon
Shares of Chuy’s Holdings, Inc. (NASDAQ:CHUY) rose sharply in today's pre-market trading after the company and Darden Restaurants, Inc. (NYSE:DRI) jointly announced that Darden will acquire Chuy's Holdings. Chuy's Holdings and Darden entered into a definitive agreement in which Darden will acquire all of Chuy's outstanding stock for $37.50 per share in cash. The all-cash transaction has an enterprise value of approximately $605 million. Chuy’s Holdings shares jumped 47.4% to $37.27 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Onconetix, Inc. (NASDAQ:ONCO) gained 65% to $0.2458 in pre-market trading. On July 15, Onconetix announced cl
Shares of ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) fell sharply during Wednesday's session after the company announced that its Singapore-incorporated, sole operating subsidiary has filed for voluntary liquidation. ASLAN Pharmaceuticals shares dipped 38.7% to $0.68 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Aptevo Therapeutics Inc. (NASDAQ:APVO) shares climbed 84% to $0.6073 after surging around 10% on Tuesday. Aptevo Therapeutics recently announced closing of $2.75 million offering. Shimmick Corporation (NASDAQ:SHIM) shares climbed 49% to $3.0173 after the company received a $27.6 million subcontract for the Sunol Valley Water Trea